DexCom, Inc. $DXCM Shares Bought by Premier Fund Managers Ltd

Premier Fund Managers Ltd boosted its holdings in shares of DexCom, Inc. (NASDAQ:DXCM) by 37.0% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 217,086 shares of the medical device company’s stock after purchasing an additional 58,588 shares during the quarter. Premier Fund Managers Ltd owned approximately 0.06% of DexCom worth $14,425,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also made changes to their positions in DXCM. GAMMA Investing LLC raised its stake in shares of DexCom by 2.5% during the 3rd quarter. GAMMA Investing LLC now owns 7,043 shares of the medical device company’s stock worth $474,000 after buying an additional 169 shares during the period. Inspire Investing LLC increased its holdings in DexCom by 6.1% in the 3rd quarter. Inspire Investing LLC now owns 3,139 shares of the medical device company’s stock worth $211,000 after acquiring an additional 180 shares in the last quarter. Personal CFO Solutions LLC raised its position in DexCom by 5.0% during the third quarter. Personal CFO Solutions LLC now owns 3,864 shares of the medical device company’s stock worth $260,000 after acquiring an additional 185 shares during the period. Inspire Advisors LLC lifted its holdings in DexCom by 2.5% during the third quarter. Inspire Advisors LLC now owns 7,926 shares of the medical device company’s stock valued at $533,000 after purchasing an additional 194 shares in the last quarter. Finally, Integrated Wealth Concepts LLC lifted its holdings in DexCom by 6.3% during the first quarter. Integrated Wealth Concepts LLC now owns 3,329 shares of the medical device company’s stock valued at $227,000 after purchasing an additional 196 shares in the last quarter. 97.75% of the stock is currently owned by hedge funds and other institutional investors.

DexCom Trading Up 1.1%

Shares of DexCom stock opened at $73.08 on Friday. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.88 and a quick ratio of 1.59. The stock’s 50 day simple moving average is $69.49 and its 200-day simple moving average is $69.31. The stock has a market cap of $28.13 billion, a P/E ratio of 34.80, a P/E/G ratio of 1.42 and a beta of 1.49. DexCom, Inc. has a 1-year low of $54.11 and a 1-year high of $91.87.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings data on Thursday, February 12th. The medical device company reported $0.68 EPS for the quarter, topping analysts’ consensus estimates of $0.65 by $0.03. The firm had revenue of $1.26 billion for the quarter, compared to the consensus estimate of $1.25 billion. DexCom had a return on equity of 32.12% and a net margin of 17.94%.The firm’s revenue was up 13.1% compared to the same quarter last year. During the same quarter last year, the business posted $0.45 earnings per share. Analysts predict that DexCom, Inc. will post 2.03 EPS for the current fiscal year.

Analyst Ratings Changes

A number of analysts have recently commented on DXCM shares. Argus cut their target price on shares of DexCom from $100.00 to $90.00 and set a “buy” rating for the company in a research note on Friday, November 7th. TD Cowen lowered their price objective on DexCom from $100.00 to $84.00 and set a “buy” rating on the stock in a report on Friday, October 31st. Truist Financial reiterated a “buy” rating and set a $80.00 price objective (down from $82.00) on shares of DexCom in a research note on Tuesday, February 17th. UBS Group decreased their target price on DexCom from $106.00 to $95.00 and set a “buy” rating on the stock in a research report on Monday, November 3rd. Finally, Robert W. Baird set a $87.00 price target on DexCom in a research note on Friday, February 13th. Two research analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating, four have given a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat, DexCom has a consensus rating of “Moderate Buy” and an average price target of $85.18.

About DexCom

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.